What Coffergamin Treats: Main Uses and Benefits

Coffergamin is commonly used for the acute management of established vascular headaches, specifically migraine and cluster headaches, where the combination is considered relevant for managing such episodes. It is generally applied in clinical settings where the patient experiences a sudden, high-intensity episode, and may provide symptomatic support during the episodic and recurrent manifestations of these painful conditions.

Easing Severe, Throbbing Head Pain

The medication is used for managing the intense symptom cluster defined by severe, pulsating cephalgia—the debilitating, throbbing pain in the head. It can provide support that helps ease the overall symptom load during the heightened pain manifestations, contributing to a more manageable experience during the episode. This treatment is relevant for conditions presenting with acute or recurrent manifestations, which include migraine, migraine variants, and cluster headache syndromes.

Intervention for Difficult-to-Treat Attacks

Coffergamin is often reserved as a specific therapeutic option for patients whose acute severe attacks are not adequately controlled by simpler, general pain relievers. This use classification is applied when appropriate, as it may assist with managing functional strain and discomfort caused by the episode in individuals with difficult-to-treat or long-duration headaches. It is used across domains where short-term symptom management is appropriate, offering supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Relief for Acute Vascular Headaches
Primary Use Focus	Acute management of migraine and cluster headache attacks.
Symptom Relevance	Severe, pulsating head pain and associated functional strain.
Typical Context	Reserved for high-intensity episodes that resist simpler analgesia.

Regulatory References

1. NIH MedlinePlus overview of Ergotamine and Caffeine

Eligibility Map: Who can and cannot use Coffergamin — Official Regulatory Information

Classification	Official Regulatory Statement
Populations for whom use is allowed (as stated in label):	Adults with vascular headaches for whom use is indicated and no contraindications exist.
Populations for whom use is not recommended (if applicable):	Pediatric patients (under 18 years); Geriatric patients (over 65 years).
Populations for whom use is contraindicated:	Women who are or may become pregnant; Patients with Peripheral Vascular Disease or Coronary Heart Disease; Patients with Uncontrolled Hypertension or Sepsis; Patients with severe renal impairment or severe hepatic impairment; Known hypersensitivity to any component.
Age-related eligibility rules:	Pediatric (under 18): Safety and efficacy are not established; not recommended. Geriatric (over 65): Use is not recommended due to limited data.
Pregnancy and lactation eligibility status (if explicitly documented):	Pregnancy: Contraindicated (Category X). Lactation: Contraindicated / Not Recommended; discontinuation of nursing or the drug is required.

Official eligibility statements:

• Coffergamin is contraindicated in women who are or may become pregnant.
• The medicine must not be used by individuals with existing Peripheral Vascular Disease or Coronary Heart Disease.
• Use is contraindicated in patients with severe hepatic or severe renal impairment.

Connection to the overall eligibility profile:

Official regulatory documents define the eligibility for Coffergamin by strictly excluding populations susceptible to its potent vasoconstrictive effects. Consequently, eligibility is generally restricted to adults without documented cardiovascular risk factors or compromise in major metabolic and excretory organs, and use is absolutely contraindicated during pregnancy or lactation.

Interactions with other medicines and products

Coffergamin's interaction profile is primarily defined by the Ergotamine component's metabolism and effects on blood vessels, as documented in regulatory labeling.

Contraindicated Combinations

Co-administration with several classes of medicinal products is formally prohibited due to the officially documented risk of serious vasoconstrictive events (ergotism) or elevated drug exposure. These combinations include:

• Potent CYP3A4 Inhibitors: Medicines such as Macrolide Antibiotics (e.g., Erythromycin), Azole Antifungals (e.g., Ketoconazole), and HIV Protease Inhibitors (e.g., Ritonavir) inhibit the metabolism of Ergotamine, leading to elevated serum levels.
• 5-HT1 Receptor Agonists (Triptans): These are contraindicated due to the regulatory classification of a risk for additive vasoconstriction.
• Other Vasoconstrictors: Use with other Ergot derivatives or pressor agents is also prohibited due to the risk of additive effects, which can cause extreme elevation of blood pressure.

---

Timing and Substance Restrictions

Regulatory documents impose specific timing constraints for interacting agents. Co-administration with a Triptan (5-HT1 agonist) must not occur within 24 hours of administering Coffergamin. Additionally, use is contraindicated in individuals with impaired hepatic or renal function due to the dependence of Ergotamine clearance on these physiological processes. Official labeling notes that heavy use of Nicotine and consumption of Grapefruit Juice may also contribute to increased interaction concern.

How Coffergamin Works

Coffergamin's action involves a dual-mechanism approach that includes vascular smooth muscle modulation and neurogenic signaling modulation.

Vascular Tone Modulation via 5-HT1B and Adrenergic Receptors

The Ergotamine component primarily functions as a partial agonist at serotonin 5-HT1B receptors and alpha-adrenergic receptors located on the smooth muscle of extracerebral blood vessels in the head. This receptor activation initiates a signal sequence that results in the sustained constriction of these vessels, counteracting the process of vasodilation.

Inhibition of Neurogenic Signaling

Ergotamine also targets pre-synaptic 5-HT1D receptors on the trigeminal nerve endings. Activation of these receptors suppresses the release of pro-inflammatory neuropeptides, such as Calcitonin Gene-Related Peptide (CGRP), thereby engaging the mechanism that reduces the intensity of localized neurogenic signaling.

Synergistic Potentiation by Caffeine

Caffeine contributes to the drug's overall effect by acting as an antagonist at Adenosine receptors. This blockade provides a mild, additive vasoconstrictive effect that works alongside Ergotamine's primary mechanism. Furthermore, Caffeine enhances the rate of absorption of Ergotamine, which facilitates the rapid attainment of concentrations required for receptor engagement.

How to Use Coffergamin

Coffergamin, a fixed-dose combination product containing Ergotamine and Caffeine, is utilized under a strictly intermittent schedule for the acute management of vascular headaches. The medication is delivered via the oral route in tablet form, with a common combination strength being 1 mg Ergotamine and 100 mg Caffeine, though a rectal suppository form also exists.

---

Administration Protocol and Dosing Limits

The established usage pattern defines both the timing and the maximum quantity permitted for administration. The recommended initial dose for the oral tablet is 2 tablets (Ergotamine 2 mg / Caffeine 200 mg), which should be taken promptly at the first sign of an acute attack to maximize potential effect. If the headache persists, subsequent supplemental doses of 1 tablet may be taken, with a required interval of 30 minutes between doses.

Usage is tightly regulated by cumulative limits: administration must not exceed a total of 6 tablets during any single headache episode. Furthermore, total weekly consumption is restricted to a maximum of 10 tablets (Ergotamine 10 mg / Caffeine 1000 mg) within a seven-day period. This strict intermittent application prohibits the product from being used for chronic daily administration. The tablets may be taken with or without food, as directed in the prescribing information.

---

Population and Procedural Context

Data indicates that the safety and effectiveness of this specific combination have not been established in pediatric patients or in individuals over 65 years of age. The procedural usage structure is designed solely for abrupt intervention, making rules for missed doses irrelevant, as the product is only administered on an as-needed basis to abort an attack.

Research Evidence / Overview of studies for Coffergamin

---

Evidence Base for Acute Migraine Attacks

Research has examined Coffergamin in the context of acute migraine attacks, focusing on conditions characterized by episodic manifestations of pain. The evidence base includes a long history of Randomized Controlled Trials (RCTs), where the combination was observed in adult populations presenting with acute, moderate-to-severe migraine symptoms. These studies primarily compared the combination of Ergotamine and Caffeine against an inactive treatment or against other active anti-migraine medications.

Researchers monitored outcomes related to physical discomfort, specifically measuring the number of patients whose pain intensity changed to reflect a headache response or who reported a pain-free status within a few hours of treatment. The studies also reported patterns observed in associated symptoms, such as nausea and sensitivity to light and sound, monitoring them over defined time intervals.

While the evidence contributes to understanding symptom patterns, studies reported measurements of headache response that were mixed when compared to newer, alternative acute migraine treatments. Additionally, research highlights that the tablet formulation appears to have lower levels of the drug reach the bloodstream (a concept called low oral bioavailability), which is a limitation noted in the studies. The findings also indicate that the measurements were influenced by early dosing—studies explored outcomes in patients who began treatment at the very first signs of the headache.

Research on Cluster Headache Episodes

The combination medicine was evaluated in the context of cluster headache episodes, which are conditions associated with acute or disruptive episodes of pain. The research foundation relies primarily on historical clinical observations and expert consensus guidelines, rather than a broad base of Randomized Controlled Trials for the oral tablet formulation.

Studies explored outcomes related to attack termination and measured the time to change in symptom intensity following administration, which are crucial outcomes for these short, severe attacks. Patient-reported data and comparative surveys, which are relevant in trials assessing episodic symptom patterns, have described patterns observed in the studies. Research highlights patterns indicating that the onset of measured change in the oral formulation may be slower than other administration methods.

---

Long-Term Observations and Follow-Up Data

Studies relevant in trials assessing short-term or episodic symptom patterns, primarily focused on the acute period immediately following the migraine or cluster headache event. Follow-up durations were typically limited to the initial 24 to 48 hours to monitor immediate response and short-term headache recurrence.

---

Evidence in Specific Patient Populations

The research has mostly focused on adults presenting with acute symptoms, and the results apply only to the populations studied. Data for certain groups remain insufficient, and studies highlight that the medicine was not fully evaluated in other specific populations.

For example, there is limited information available from clinical trials regarding the use of Coffergamin in children or adolescents. Similarly, evidence quality varies across studies when examining older adults or patients with coexisting health conditions.

---

Areas of Research Uncertainty and Study Limitations

Scientific reviews and studies contribute to the broader evidence landscape by highlighting several areas where certainty remains low or where the data show patterns related to research limitations. The sample sizes were modest in some key trials, and evidence quality varies across studies, which may lead to mixed findings in the literature. Certainty remains low regarding the overall profile when comparing the combination to some newer acute treatments, as comparative evidence is noted as lacking or showing less favorable short-term measurements.

Key Studies & References

1. MedlinePlus: Ergotamine and Caffeine Drug Information
2. MedlinePlus: Drug Information (General Overview of Combination Products)

Common questions about Coffergamin (FAQ)

---

Q: Does Coffergamin cause stomach upset?

Official labeling indicates that gastrointestinal effects are frequently reported with this medicine. These reactions include nausea, vomiting, and abdominal pain (stomach pain).

---

Q: Can Coffergamin affect my sleep patterns?

Regulatory documents state that Coffergamin may affect sleep. Insomnia (trouble sleeping) and restlessness are listed as possible side effects of the medication.

---

Q: Does taking Coffergamin make you feel tired or drowsy?

Official labeling indicates that drowsiness and somnolence (a state of sleepiness) have been reported as rare side effects. This means that feeling tired is a possibility for some individuals using the medicine.

---

Q: Is it normal to feel a change in appetite when starting Coffergamin?

Regulatory documents list anorexia, or a loss of appetite, as a reported adverse reaction. While the incidence rate is not always known, a change in appetite is listed among the possible effects of the medicine.

---

Q: Does Coffergamin cause weight gain or weight loss?

Official labeling does not list general weight changes as a common or known side effect. However, anorexia (loss of appetite) has been reported as an adverse reaction in regulatory documents, though its incidence is unknown.

---

Q: Are there studies on how Coffergamin affects mood?

Side effect reports found in official documentation include neurological symptoms such as nervousness and anxiety. These reports indicate that the medication may affect emotional and neurological states.

---

Q: Can I take Coffergamin before driving or operating machinery?

Official labeling contains warnings about engaging in activities that require alertness. The official patient information indicates that, due to potential side effects like dizziness or drowsiness, caution should be exercised before driving or operating machinery.

---

Q: What are the signs of a serious allergic reaction to Coffergamin?

Official regulatory information describes the signs associated with a serious allergic reaction. These signs may include hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.

---

Q: What is the main purpose of the black box warning on Coffergamin, if it has one?

The primary purpose of the Boxed Warning is to emphasize the danger of combining Coffergamin with strong CYP3A4 inhibitor medicines. This combination significantly increases the risk of serious and life-threatening complications, such as a lack of blood flow to the limbs (peripheral ischemia) or stroke (cerebral ischemia).

---

Q: Does Coffergamin have a 'black box' warning?

Official labeling confirms that the product includes a Boxed Warning, which is the formal name for the severe safety precaution often referred to as a 'black box' warning.

---

Q: What kind of monitoring is needed while taking Coffergamin?

Due to the risk of serious blood vessel constriction, regulatory documents highlight that observation for signs of peripheral ischemia (poor circulation in the limbs) is necessary. The warnings also note the need to observe cardiovascular effects like high blood pressure.

---

Q: What is the risk of dependence or addiction with Coffergamin?

Official labeling includes warnings that using the medicine for long-term, continuous periods may lead to the medication becoming habit-forming. Furthermore, regulatory documents report instances of withdrawal headaches following such prolonged use.

---

Q: Can I stop taking Coffergamin suddenly?

Official information warns against prolonged or continuous daily use of Coffergamin. If the medicine has been used excessively and is then stopped suddenly, individuals may experience withdrawal symptoms such as rebound headaches, nausea, and vomiting.

---

Q: Is it possible for Coffergamin to stop working over time?

Official documentation prohibits the use of the medicine for prolonged daily administration. This is because regulatory reports have noted medication-overuse headaches, where the treatment itself can contribute to more frequent headaches.

---

Q: Can Coffergamin be crushed or split?

Official product information does not provide any instructions for crushing or splitting the tablets. In the absence of specific instructions, the integrity of the tablet should be maintained, and it should be swallowed whole.

---

Q: Are there any common food or drink restrictions while using Coffergamin?

Official labeling indicates the need to limit alcoholic beverages while using the medicine. Additionally, regulatory documents state that caution is required regarding the consumption of products containing Grapefruit or Grapefruit juice.

---

Q: Can I drink alcohol while using Coffergamin? (informational only)

Official labeling contains a statement advising individuals to limit alcoholic beverages. This is based on the rationale that alcohol itself may contribute to or trigger headaches.

---

Q: Does Coffergamin interact with caffeine?

Coffergamin itself contains caffeine. Because of this, regulatory documents contain warnings about combining the medicine with other stimulants, as this may increase the risk of hypertension or vasospasm (severe blood vessel constriction).

---

Q: Does Coffergamin interact with common over-the-counter pain relievers?

Official labeling cautions that the ergotamine component can interact with certain drugs to increase the risk of high blood pressure (hypertension). This potential for additive vascular effects means that caution is noted if other over-the-counter pain relievers also affect blood pressure or blood vessels.

---

Q: Does Coffergamin interact with birth control pills?

Official patient counseling information contains a recommendation that women of childbearing age use two effective forms of birth control. This is due to the medicine's absolute contraindication during pregnancy.

---

Q: Is Coffergamin an anti-inflammatory drug?

Regulatory classifications define this medicine as an ergot alkaloid and an antimigraine agent. It is not classified as a non-steroidal anti-inflammatory drug (NSAID) or a general anti-inflammatory medicine.

---

Q: Is Coffergamin a narcotic?

Official regulatory references indicate that the medicine is not classified as a narcotic.

---

Q: Is Coffergamin considered a controlled substance?

According to official regulatory references, the active ingredients in Coffergamin are not classified as controlled substances under the US Controlled Substances Act (CSA), though ergotamine is regulated as a List I chemical.

---

Q: Are there different brand names for the medicine Coffergamin?

The combination medicine is/was available under various brand names. Some historically used or known brand names include Cafergot and Migergot.

---

Q: Is a generic version of Coffergamin available?

Lower-cost generic versions of the ergotamine and caffeine combination are generally available.

---

Q: What are the inactive ingredients in the Coffergamin tablet?

Official product descriptions and documents include complete lists of the inactive ingredients (also called excipients). These non-active components can vary depending on the specific manufacturer of the tablet.

The storage and disposal of Ergotamine Tartrate and Caffeine Tablets (Coffergamin) must strictly follow official regulatory guidelines to maintain product quality and ensure safety.

---

Storage Conditions

Requirement	Official Specification
Temperature	Store at Controlled Room Temperature (20 C to 25 C) .
Protection	Must be kept in a tight, light-resistant container and protected from freezing and excess heat.

---

Handling and Disposal

Official labeling mandates that the medicine must be kept out of the reach of children. Regarding disposal, patients should ask a healthcare professional for guidance on how to properly discard any unused or outdated medicine; do not keep medication that is no longer needed. Safe disposal methods ensure compliance with environmental regulations for pharmaceutical waste.